Adynxx IncOver The Counter Market:ADYX
- LAST PRICE0.0001
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots---/ ---
- Ask / Lots---/ ---
- Open / Previous Close--- / 0.0001
- Day Range---
- 52 Week Range
- Volume---
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Adynxx Inc | 580.0 | 0.0x | --- |
Drazcanna Inc | 164.2K | 0.0x | --- |
Seelos Therapeutics Inc | 170.0K | 0.0x | --- |
Aeolus Pharmaceuticals Inc | 150.0 | 0.0x | --- |
DNAPrint Genomics Inc | 640.0 | 0.0x | --- |
Regenerative Medical Technology Group Inc | 395.0K | 0.0x | --- |
Company Information
Adynxx, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of a new class of therapeutics called transcription factor decoys and bringing to market disease-modifying products to address unmet needs in the treatment of pain and inflammation. The Company has leveraged its AYX platform of proprietary transcription factor decoys to identify and develop product candidates designed to modify the course of pain. Its product pipeline includes Brivoligide for postoperative pain and AYX2 for chronic pain. Brivoligide is a transcription factor decoy specifically designed to inhibit the function of transcription factor Early Growth Response 1 (EGR1), in the dorsal root ganglia (DRG), and spinal cord when administered at the time of surgery. Its second product candidate, AYX2, is a transcription factor decoy targeting the activity of specific members of the KLF family of transcription factors, including KLF6, KLF9 and KLF15.
Contact Information
- Headquarters
- 100 Pine St Ste 500SAN FRANCISCO, CA, United States 94111-5103
- Phone
- 415-512-7740
- Fax
- 215-702-8535
Executives
- Chairman of the Board
- Dennis Podlesak
- Chief Executive Officer, Principal Financial Officer, Director
- Rick Orr
- Chief Scientific Officer, Director
- Julien Mamet
- Chief Medical Officer
- Donald Manning
- Director
- Stan Abel
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $580.00 |
|---|---|
Revenue (TTM) | $460.0K |
Shares Outstanding | 5.8M |
Adynxx Inc does not pay a dividend. | |
Beta | --- |
EPS | $-3.58 |
Book Value | $9.89 |
P/E Ratio | 0.0x |
Price/Sales (TTM) | 0.0 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -1,607.17% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
